Anna D. Krasnodembskaya, Ph.D., has been named STEM CELLS’ Young Investigator of 2017 for her investigations into stem cell-based therapies for acute respiratory distress syndrome (ARDS). The award fosters advancements in the field of stem cells and regenerative medicine by honoring a young researcher who is principle author of an article published in STEM CELLS that is deemed to have the most impact and to push the boundaries of novel and insightful research.
You are here
Press Releases from AlphaMed Press
Embargo Policy: Articles for STEM CELLS and STEM CELLS Translational Medicine are embargoed for release until 9 a.m. Eastern U.S. time on the day the article is posted online. This policy applies to members of the media, authors, institutions' public information officers, and the public. Authors may not discuss their work with the media until 1 week before the mailing date or 1 week before online posting of the article, whichever is earlier, and must ensure that the media representatives agree to abide by the embargo policy. STEM CELLS Translational Medicine may refuse to publish a manuscript, despite acceptance for publication, if it has been prematurely released to the press.
A long-term study of patients who received stem cells to treat angiitis-induced critical limb ischemia (AICLI) shows the cells to be both safe and effective. The study, published in STEM CELLS Translational Medicine (SCTM), could lead to an option for those who suffer from this serious form of peripheral arterial disease (PAD).
A new line of human stem cells shows promise for one day advancing treatment for epileptic seizures. As reported in STEM CELLS Translational Medicine (SCTM), the cells are designed to deliver adenosine – which calms down overexcited neurons and protects them from damage -- to the central nervous system (CNS). The research was conducted by scientists at the University of Bonn and the Central Institute of Mental Health (CIMH) in Mannheim.
Smoking dramatically decreases the regenerative ability of stem cells, according to a study recently published in the journal STEM CELLS. These findings suggest that a smoker in need of stem cell therapy might fare better if the cells he receives are donated by a nonsmoker — counter to the alternative approach of using the patient’s own stem cells whenever possible to reduce the chance of rejection.
A new study appearing in STEM CELLS Translational Medicine demonstrates the promise of a type of cell found in the placenta in helping those suffering from painful and life-threatening severe acute graft-versus-host disease (GvHD). GvHD occurs in up to 70 percent of patients who have undergone a stem cell transplant to treat a disease such as leukemia, using cells other than their own. GvHD develops because the donor's immune cells attack the patient's normal cells.
A new study appearing in STEM CELLS Translational Medicine (SCTM) shows how understanding the way a type of molecule called CD133 functions might contribute to an understanding of the mechanisms involved in kidney repair.
Kidney injuries affect up to 7 percent of hospitalized patients, with those in intensive care especially vulnerable. An increasing amount of evidence indicates that although the kidney might seem to regain normal function, in fact it remains permanently damaged.
Studies conducted on mice have shown that stem cell therapy is a possible path to total kidney repair. That's why scientists are interested in the CD133 molecule.
STEM CELLS Translational Medicine (SCTM) named Philippe Lysy, M.D., Ph.D., the STEM CELLS Translational Medicine’s Young Investigator of 2017 for his exploration of new sources of cells capable of conversion into insulin-secretors. The award fosters advancements in the field of stem cells and regenerative medicine by honoring a young researcher who is principle author of an article published in SCTM that is deemed to have the most impact and to push the boundaries of novel and insightful research.
In a new study published in STEM CELLS Translational Medicine, researchers used a type of platelet-derived growth factor called PDGF-BB that enhances cells’ ability to regenerate dentin-pulp complex.
Many in the medical community view stem cell therapy as a promising new strategy for repairing teeth once thought to be irreversibly damaged by tooth decay or dental injuries. The benefits of human dental pulp stem cells (hDPSCs), isolated from the living connective tissue in the tooth’s center, on such damage have been well documented in studies.
DURHAM, NC - Each year in the United States more than 300,000 people are hospitalized for hip fractures. Almost half never recover well enough to live an independent lifestyle and, even worse, the one-year mortality rate is high, ranging from 12 percent to 37 percent.
A new review is the first to directly examine the role of various stem cells in the healing of wounded cornea, the outermost part of the eye. In contrast with most other reviews, it covers all major corneal cell types in a comprehensive way, showing similarities and differences in the healing process and the usage of stem cells for therapy.
Corneal wound healing is a complex process that occurs in response to various eye injuries and surgery. Delayed, incomplete, or excessive healing is a significant clinical concern. The review presents evidence on the participation of stem cells in corneal wound healing and highlights how stem cell transplantation may be used to fine tune wound healing and provide benefits for patients.